RARE
Ultragenyx
NASDAQ: RARE · HEALTHCARE · BIOTECHNOLOGY
$24.18
-1.43% today
Updated 2026-04-29
Market cap
$2.38B
P/E ratio
—
P/S ratio
3.53x
EPS (TTM)
$-5.83
Dividend yield
—
52W range
$18 – $42
Volume
2.0M
Ultragenyx (RARE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $133000.00 | $2.61M | $51.49M | $103.71M | $271.03M | $351.41M | $363.33M | $434.25M | $560.23M | $673.00M |
| Revenue growth (YoY) | — | — | — | — | — | — | +1863.9% | +1871.5% | +101.4% | +161.3% | +29.7% | +3.4% | +19.5% | +29.0% | +20.1% |
| Cost of revenue | — | — | — | $0.00 | $1.38M | $183.20M | $1000.00 | $1.15M | $9.01M | $6.13M | $16.01M | $28.32M | $45.21M | $76.73M | $109.00M |
| Gross profit | — | — | — | $0.00 | $-1.38M | $133000.00 | $2.61M | $50.35M | $94.71M | $264.90M | $335.40M | $335.01M | $389.04M | $483.50M | $564.00M |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | 97.8% | 91.3% | 97.7% | 95.4% | 92.2% | 89.6% | 86.3% | 83.8% |
| R&D | $4.72M | $12.64M | $27.83M | $45.97M | $114.74M | $183.20M | $231.64M | $294.00M | $357.36M | $412.08M | $497.15M | $705.79M | $648.45M | $697.87M | $750.00M |
| SG&A | $1.84M | $3.34M | $4.45M | $10.81M | $33.00M | $64.94M | $99.91M | $127.72M | $161.52M | $182.93M | $219.98M | $278.14M | $309.80M | $321.61M | $349.00M |
| Operating income | $-6.56M | $-15.98M | $-32.28M | $-56.78M | $-147.74M | $-248.01M | $-328.94M | $-371.37M | $-424.17M | $-330.12M | $-381.74M | $-648.92M | $-569.21M | $-535.97M | $-535.00M |
| Operating margin | — | — | — | — | — | -186471.4% | -12593.5% | -721.2% | -409.0% | -121.8% | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| EBITDA | $-6.54M | $-16.02M | $-34.63M | $-56.09M | $-146.35M | $-244.58M | $-323.12M | $-177.56M | $-389.77M | $-139.81M | $-410.32M | $-640.49M | $-516.45M | $-469.00M | $-500.00M |
| EBITDA margin | — | — | — | — | — | -183897.0% | -12370.5% | -344.8% | -375.8% | -51.6% | -116.8% | -176.3% | -118.9% | -83.7% | -74.3% |
| EBIT | $-6.58M | $-16.33M | $-35.07M | $-56.78M | $-147.74M | $-248.01M | $-328.94M | $-197.10M | $-398.31M | $-152.07M | $-423.56M | $-658.71M | $-542.46M | $-504.55M | $-535.00M |
| Interest expense | $270000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.14M | $33.29M | $29.42M | $43.02M | $66.00M | $63.04M | $62.00M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6.85M | $-16.33M | $-35.07M | $-59.80M | $-145.62M | $-245.87M | $-302.14M | $-197.61M | $-402.73M | $-186.57M | $-454.02M | $-707.42M | $-606.64M | $-569.18M | $-575.00M |
| Net income growth (YoY) | — | -138.5% | -114.7% | -70.5% | -143.5% | -68.8% | -22.9% | +34.6% | -103.8% | +53.7% | -143.4% | -55.8% | +14.2% | +6.2% | -1.0% |
| Profit margin | — | — | — | — | — | -184867.7% | -11567.3% | -383.7% | -388.3% | -68.8% | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% |